MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

Mark Kerstjens; Emma Driessen; Merel Willekes; Sandra Mimoso Pinhancos; Pauline Schneider; Rob Pieters; Ronald Stam

doi:10.18632/oncotarget.11730

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

Mark Kerstjens, Emma Driessen, Merel Willekes, Sandra Mimoso Pinhancos, Pauline Schneider, Rob Pieters, Ronald Stam

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

41 Citations (Scopus)

22 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	14835-14846
Number of pages	12
Journal	Oncotarget
Volume	8
Issue number	9
DOIs	https://doi.org/10.18632/oncotarget.11730
Publication status	Published - 2017

Research programs

EMC MM-02-54-03

Access to Document

10.18632/oncotarget.11730

REPUB_98211_OA.pdfFinal published version, 2.53 MB

http://hdl.handle.net/1765/98211

Cite this

@article{92d2b5539323433199584f1aa2b37d20,

title = "MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations",

author = "Mark Kerstjens and Emma Driessen and Merel Willekes and {Mimoso Pinhancos}, Sandra and Pauline Schneider and Rob Pieters and Ronald Stam",

year = "2017",

doi = "10.18632/oncotarget.11730",

language = "Undefined/Unknown",

volume = "8",

pages = "14835--14846",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "9",

}

TY - JOUR

T1 - MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

AU - Kerstjens, Mark

AU - Driessen, Emma

AU - Willekes, Merel

AU - Mimoso Pinhancos, Sandra

AU - Schneider, Pauline

AU - Pieters, Rob

AU - Stam, Ronald

PY - 2017

Y1 - 2017

U2 - 10.18632/oncotarget.11730

DO - 10.18632/oncotarget.11730

M3 - Article

C2 - 27588400

SN - 1949-2553

VL - 8

SP - 14835

EP - 14846

JO - Oncotarget

JF - Oncotarget

IS - 9

ER -